Compare · HSDT vs LIVN
HSDT vs LIVN
Side-by-side comparison of Solana Company (HSDT) and LivaNova PLC (LIVN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HSDT and LIVN operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- LIVN is the larger of the two at $4.11B, about 51.0x HSDT ($80.6M).
- Over the past year, HSDT is down 96.7% and LIVN is up 61.5% - LIVN leads by 158.2 points.
- HSDT has been more active in the news (14 items in the past 4 weeks vs 5 for LIVN).
- LIVN has more recent analyst coverage (20 ratings vs 3 for HSDT).
- Company
- Solana Company
- LivaNova PLC
- Price
- $1.38+9.52%
- $74.83+3.48%
- Market cap
- $80.6M
- $4.11B
- 1M return
- -36.11%
- +5.57%
- 1Y return
- -96.71%
- +61.48%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 14
- 5
- Recent ratings
- 3
- 20
Solana Company
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-implantable investigational medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.
LivaNova PLC
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
Latest HSDT
- Director Jiang Cosmo Yi exercised 1,005,040 shares at a strike of $0.00 and covered exercise/tax liability with 610 shares (SEC Form 4)
- SEC Form 4 filed by Director Jiang Cosmo Yi
- Solana Company filed SEC Form 8-K: Entry into a Material Definitive Agreement
- SEC Form 424B5 filed by Solana Company
- SEC Form SD filed by Solana Company
- Director Straw Edward M was granted 6,360 shares, increasing direct ownership by 291% to 8,542 units (SEC Form 4)
- Director Mello Sergio was granted 6,360 shares (SEC Form 4)
- Director Lee Michel Kai Tai was granted 6,360 shares (SEC Form 4)
- Director Walter Blane was granted 6,360 shares, increasing direct ownership by 291% to 8,542 units (SEC Form 4)
- Amendment: Director Straw Edward M was granted 2,180 shares, increasing direct ownership by 109,000% to 2,182 units (SEC Form 4)
Latest LIVN
- LivaNova Appoints Anne Liddy as Chief Legal Officer
- SEC Form SD filed by LivaNova PLC
- Director Bianchi Francesco sold $136,350 worth of Ordinary Shares (1,800 units at $75.75), decreasing direct ownership by 20% to 7,228 units (SEC Form 4)
- LivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit
- LivaNova to Present at Goldman Sachs Global Healthcare Conference in June
- SEC Form IRANNOTICE filed by LivaNova PLC
- SEC Form 10-Q filed by LivaNova PLC
- LivaNova PLC filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- LivaNova Reports First-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
- Amendment: SEC Form SCHEDULE 13G/A filed by LivaNova PLC